Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07270198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression

Study acronym: PERSONALISEDKD
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages 1 to 3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i. The main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline in the above mentioned patients who are on chronic SGLT2i therapy.
Trial Details
NCT Number NCT07270198
Lead Sponsor Mario Negri Institute for Pharmacological Research
Conditions
(from sponsor)		 Diabetic Kidney Disease (DKD)
Related terms Diabetic Nephropathies
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov